Xinermei (mazdutide) / Eli Lilly, Innovent Biologics - LARVOL DELTA

Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial. (PubMed, Med) - "Mazdutide 9 mg was safe and led to substantial weight reductions in Chinese adults with a BMI ≥ 30kg/m2 but without diabetes after 24-week treatment. These results support further clinical development of mazdutide 9 mg for the treatment of obesity."

Clinical • Journal • P2 data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Mazdutide, a GCGR/GLP-1R Dual Agonist, Alleviates MASH and Liver Fibrosis through Hepatocytes–Hepatic Stellate Cells Cross Talk (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

Effect of Mazdutide on Kidney Function in Adults with Obesity or Overweight (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Metabolic Disorders • Obesity

Mazdutide Improves Markers of Insulin Sensitivity in Adults with Obesity without Type 2 Diabetes (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Mazdutide vs. Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomised, Open-Label, Phase 3b Trial (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • P3 data • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Efficacy and Safety of Mazdutide 9 mg in Chinese Adults with Obesity: Results from the Phase 3 GLORY-2 Trial (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • P3 data • Metabolic Disorders • Obesity

Safety, Tolerability, and Pharmacokinetics of Once-Weekly Mazdutide in Chinese Adolescents with Obesity: A Phase 1b Trial (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • P1 data • PK/PD data • Metabolic Disorders • Obesity

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. (PubMed, Endocrinol Diabetes Metab) - "Retatrutide and survodutide exhibit the most favourable efficacy profiles for obesity and T2DM, with acceptable safety. These findings support their potential clinical use and highlight the need for future head-to-head trials."

Journal • Retrospective data • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity (clinicaltrials.gov) - P3 | N=336 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

New P3 trial • Cardiovascular • Genetic Disorders • Hypertension • Obesity • CST3

Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials. (PubMed, Diabetes Obes Metab) - "Mazdutide effectively reduces weight, waist circumference and blood pressure but may cause mild to moderate adverse events. Findings are limited by the small number of RCTs."

Journal • Retrospective data • Review • Genetic Disorders • Metabolic Disorders • Obesity

Patent landscape and therapeutic evolution of Mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes. (PubMed, Expert Opin Ther Pat) - "Mazdutide illustrates how layered patent strategies integrating molecular design, manufacturability, formulation stability, and clinical use claims can secure durable exclusivity. This approach provides a strategic model for future dual and multi-receptor peptide therapeutics."

Journal • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis. (PubMed, Cardiol Rev) - "Incretin-based dual and triple agonists have emerged as effective options for obesity management, offering enhanced weight loss through multi-receptor agonism...A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults...No significant difference was found in serious AEs (RR 0.87; 95% CI: 0.65-1.14). In conclusion, incretin-based polyagonists were associated with significant weight reduction and improved metabolic outcomes compared to placebo."

Journal • Retrospective data • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management. (PubMed, Diabetes Metab Syndr Obes) - "Dulaglutide, semaglutide, polyethylene glycol loxenatide, tirzepatide, and mazdutide were evaluated using a 100-point scoring system based on drug labels, systematic literature review, and real-world data. This evaluation identifies semaglutide and dulaglutide as the preferred long-acting GLP-1RAs in China's current therapeutic landscape. The standardized, transparent six-dimensional framework provides a replicable methodology for the comprehensive assessment of chronic disease therapies, supporting rational drug selection and resource allocation."

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

DREAMS-3: A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity (clinicaltrials.gov) - P3 | N=349 | Active, not recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Trial primary completion date: Feb 2026 ➔ Sep 2025

Trial primary completion date • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (clinicaltrials.gov) - P3 | N=912 | Not yet recruiting | Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Monotherapy • New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy, Safety, and Tolerability of a GLP-1/GCG Dual Receptor Agonist in Type 2 Diabetes with Early Dementia: A Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Trial (ChiCTR) - P4 | N=420 | Recruiting | Sponsor: Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University; Nanjing Drum Tower Hospital, Affiliated Hospital of Medical Sc

New P4 trial • Alzheimer's Disease • CNS Disorders • Dementia • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Study on the Efficacy and Safety of Mazdutide in Systemic Lupus Erythematosus (ChiCTR) - P=N/A | N=20 | Not yet recruiting | Sponsor: Ruijin Hospital: Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital; Ruijin Hospital: Shanghai Jiao Tong University Medical Schoo

New trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Study of IBI362 in Chinese Adolescents With Obesity or Overweight (clinicaltrials.gov) - P3 | N=180 | Recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies. (PubMed, Front Endocrinol (Lausanne)) - "This article systematically reviews the current various intervention methods and research status for the treatment of hyperuricemia: In the field of Western medicine, it deeply analyzes the efficacy, mechanism of action, and clinical limitations of drugs that promote uric acid excretion (such as benzbromarone and dotinurad), drugs that inhibit uric acid synthesis (such as allopurinol, febuxostat, and topiroxostat), and drugs that promote uric acid hydrolysis (such as pegloticase and rasburicase). It focuses on elaborating the research breakthroughs of URAT1 inhibitor derivatives and the new drug SHR4640...At the same time, it details the action pathways and clinical evidence of emerging therapies such as SGLT2 inhibitors, the GLP-1/GCG dual-receptor agonist Mazdutide, probiotics, and washed microbiota transplantation (WMT). By summarizing mechanistic insights, clinical progress, and translational prospects, this review aims to inform the development of individualized and..."

Journal • Review • Cardiovascular • Gout • Inflammatory Arthritis • Metabolic Disorders • Rheumatology • Transplantation • GCG

IUPHAR Review: From Foe to Friend: Repurposing Glucagon to Treat Obesity and Type 2 Diabetes. (PubMed, Pharmacol Res) - "We focus our review on glucagon receptor (GCGR) agonism, which has recently been combined with both GLP-1R and GLP-1R/GIPR agonism to generate dual (e.g. survodutide, cotatutide, mazdutide, etc) and triple agonists (e.g. retatrutide, etc) for improved body weight loss via energy expenditure stimulation. Mechanistic data has only currently been evaluated in preclinical rodent models and evidence for similar processes in humans is limited. We also provide perspectives about how treatments can improve for future advancement of obesity treatment."

Journal • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon. (PubMed, J Obes) - "Currently, liraglutide, semaglutide, and tirzepatide are FDA-approved for obesity treatment, while other agents are used off-label...Novel agents including CagriSema and higher dose oral semaglutide are advancing through clinical trials, while pivotal trial results for orforglipron, mazdutide, retatrutide, and survodutide are anticipated to further expand the therapeutic landscape...The convergence of pharmacological innovation, digital health strategies, and equitable care initiatives is expected to revolutionize obesity therapeutics in the coming decade. Priorities for future research include sustaining long-term weight loss, establishing disease-modifying potential in nonmetabolic disorders, and addressing health equity concerns to ensure broader global benefit."

Journal • Review • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Diabetes • Dyslipidemia • Genetic Disorders • Heart Failure • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity (clinicaltrials.gov) - P1/2 | N=98 | Active, not recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

Mazdutide: An Investigational Glucagon Receptor and Glucagon-Like Peptide-1 Receptor Dual Agonist Injectable Treatment for Obesity and Type 2 Diabetes (ASHP 2025) - No abstract available

Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Obesity in China: current progress and future prospects. (PubMed, Lancet Diabetes Endocrinol) - "Since 2021, five additional GLP-1 receptor agonists (including liraglutide, beinaglutide, semaglutide, tirzepatide, and mazdutide) have been approved in China for weight management, broadening therapeutic choices and initiating a transformation in obesity care. These include limitations in existing diagnostic criteria for obesity which captures phenotypic and cardiometabolic heterogeneity; limited availability of quantifiable, actionable, and accountable national targets which weakens governance and evaluation; and a scarcity of evidence-based algorithms for obesity pharmacotherapy, which risks over-reliance on medication and diverts attention from socioeconomic, environmental, and behavioural determinants. We call for people-centred, integrated systems that embed whole-person obesity care within a planetary health framework and deliver a coherent continuum of prevention, treatment, and long-term support."

Journal • Review • Genetic Disorders • Obesity

Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity (PRNewswire) - "After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly superior to those observed in the placebo group (BMI reduction: 1.73%; weight reduction: 1.42 kg; with nominal P values < 0.01). Furthermore, multiple metabolic parameters improved simultaneously."

P1 data • Obesity